Keyword Analysis & Research: cassava sciences website
Keyword Research: People who searched cassava sciences website also searched
Search Results related to cassava sciences website on Search Engine
-
Cassava Sciences | Cassava Sciences, Inc.
https://www.cassavasciences.com/
WebWe Innovate. We are a clinical-stage biopharmaceutical company focused on neuroscience. We translate novel scientific insights into new medicines. That’s a drastic challenge. Our work is complex, risky, labor-intensive, persistent and expensive. And it’s what we love to do.
DA: 34 PA: 10 MOZ Rank: 41
-
Investor Relations | Cassava Sciences, Inc.
https://www.cassavasciences.com/investor-relations
WebMar 4, 2024 · Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs. Presentations. Cassava Corporate Presentation – First Quarter 2024. Warrant Distribution Q&A – Updated January 3, 2024. Warrant Prospectus Supplement (as filed with SEC) Financial Information. SEC Filings. Annual Reports. Press Releases. View all. website
website
DA: 13 PA: 81 MOZ Rank: 83
-
Science | Cassava Sciences, Inc.
https://www.cassavasciences.com/science
WebSavaDx is our blood-based investigational diagnostic to detect Alzheimer’s disease. The goal of SavaDx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms. Learn More.
DA: 3 PA: 100 MOZ Rank: 92
-
Simufilam | Cassava Sciences, Inc.
https://www.cassavasciences.com/simufilam
WebSimufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease. Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.
DA: 46 PA: 1 MOZ Rank: 5
-
PRESS RELEASES | Cassava Sciences, Inc.
https://www.cassavasciences.com/press-releases
WebNov 6, 2023 · Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates. February 7, 2024. No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months. January 5, 2024. Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders.
DA: 89 PA: 14 MOZ Rank: 16
